Last reviewed · How we verify
Intravitreal bevacizumab and dexamethasone implant Injection — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Intravitreal bevacizumab and dexamethasone implant Injection (Intravitreal bevacizumab and dexamethasone implant Injection) — Yeungnam University College of Medicine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intravitreal bevacizumab and dexamethasone implant Injection TARGET | Intravitreal bevacizumab and dexamethasone implant Injection | Yeungnam University College of Medicine | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intravitreal bevacizumab and dexamethasone implant Injection CI watch — RSS
- Intravitreal bevacizumab and dexamethasone implant Injection CI watch — Atom
- Intravitreal bevacizumab and dexamethasone implant Injection CI watch — JSON
- Intravitreal bevacizumab and dexamethasone implant Injection alone — RSS
Cite this brief
Drug Landscape (2026). Intravitreal bevacizumab and dexamethasone implant Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/intravitreal-bevacizumab-and-dexamethasone-implant-injection. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab